Blood
Articles in this Issue
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Abstract Background The JAK2 V617F mutation is the most prevalent molecular abnormality in BCR-ABL-negative myeloproliferative neoplasms, occ...
Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma
Abstract Background: Clonotypic peptide detection by mass spectrometry (MS) leverages monoclonal protein (M-protein) de novo sequencing and...
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Abstract Introduction:A comprehensive integration of significantly mutated genes and pathways with molecular subgroups is lacking in adult B...
Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study
Abstract Background Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) have dismal outcomes, representing an urgent unm...
Budesonide for melphalan-induced intestinal mucositis in autologous hematopoietic stem cell transplant: Rapid resolution with short-course therapy
Abstract Background: High-dose melphalan (HDM) is commonly used for conditioning prior to autologous stem cell transplan...
Thrombotic complications in patients with acquired factor deficiency: A national inpatient sample analysis
Abstract Introduction: Acquired factor deficiency (AFD) represents a heterogeneous group of rare coagulopathies characterized by decreased l...
Expression of natural killer cell ligands on Acute Myeloid Leukemia cells harboring various genetic and cytogenetic abnormalities
Abstract Acute myeloid leukemia (AML) is a heterogenous disease with an emerging landscape of genetic and cytogenetic abnormalities. Natural...
Quantitative 18F-FDG-PET/CT analysis of splenic suvmax enhances diagnostic accuracy in primary splenic non-Hodgkin lymphoma
Abstract Introduction Primary splenic Non-Hodgkin lymphoma (PS-NHL) is an uncommon extranodal lymphoma, representing less than 1% of all lymp...
Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)
Abstract INTRODUCTION: Hypomethylating agents continue to be the standard treatment for higher-risk MDS. However, in cases of failure or res...
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance
Abstract Stress granules (SGs) and processing bodies (PBs), assembled via liquid-liquid phase separation (LLPS), are critical for spatial re...
Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has become a standard treatment for relapsed/refractory large B-cell l...
Transfusion-related acute lung injury (TRALI) following intravenous immunoglobulin infusion in a patient with myasthenia gravis
Abstract Introduction Transfusion-related acute lung injury (TRALI) is a rare but life-threatening complication of blood...
ZBTB7A loss promotes RUNX1::RUNX1T19a-driven leukemia by enhancing the block of erythroid differentiation
Abstract ZBTB7A is a transcription factor critical for hematopoietic lineage commitment. By binding to promoter regions via its zinc fingers...
Academic vs. community care in HHV8+ DLBCL: Dissecting disparities in the HIV-positive population
Abstract Background Human herpesvirus 8–positive diffuse large B-cell lymphoma (HHV8+ DLBCL) is a rare and aggressive subtype of DLBCL, acco...
HIT immune complexes activate the inflammasome pathway in a complement-dependent manner
Abstract Background: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction to heparin caused by pathological immunoglobulin G (I...
Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)
Abstract Background: Relapsed/refractory multiple myeloma (MM) patients are at an increased risk of infectiondue to the immunsuppressive nat...
Phase I/II clinical trial of bortezomib in combination with CPX-351 for the treatment of newly-diagnosed TP53-mutated Acute Myeloid Leukemia (NCT07008638)
Abstract Background and Significance: TP53 mutant Acute Myeloid Leukemia (TP53m AML) defines the most treatment-resistan...
Baseline data from the prioritizing utilization and safety of hydroxyurea using precision in Africa (PUSHUP) trial
Abstract Background: There are >500,000 infants born with sickle cell anemia (SCA) each year, mostly (>90%) in sub-Saharan Afr...
The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)
Abstract Introduction CNL is a rare myeloproliferative neoplasm (MPN) with a 5-year-survival-rate of 28 percent, and no standard of care for...
Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl
Abstract Background and significance: T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) accounts for 15% of pediatric and 25% of a...
Regional hypometabolism on brain FDG-PET one month after receiving chimeric antigen receptor T-cell therapy may be associated with icans
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy is an established cellular therapy approved for pa...
Evaluation of new deferasirox-derived compounds for the treatment of iron overload
Abstract Introduction: Iron overload is a major complication in individuals requiring frequent blood transfusions or those with genetic iron...
Blinatumomab improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation
Abstract Background Major ABO-group incompatibility increases the risk of delayed erythroid engraftment, and other immunological complicatio...
Development of a JAK2V617F-targeting lipid nanoparticle-siRNA as a novel gene therapy for myeloproliferative neoplasms
Abstract Background A single acquired JAK2 point mutation (JAK2V617F) drives myeloproliferative neoplasm (MPN) disease in 50-60% of essentia...
A novel role for SIX1 and EYA2 and a novel EYA2 inhibitor in myeloid leukemogenesis
Abstract Background: Patients with Acute Myeloid Leukemias (AML) harboring MLLT10 (AF10) fusion oncogenes have a 5-year...